AZ505: Potent and Selective SMYD2 Inhibitor for Epigenetic and Cancer Research

Executive Summary: AZ505 is a highly selective, substrate-competitive inhibitor of SMYD2, a protein lysine methyltransferase implicated in epigenetic regulation and cancer biology. It inhibits SMYD2 with an IC₅₀ of 0.12 μM and demonstrates minimal off-target activity against related methyltransferases (IC₅₀ > 83.3 μM) [APExBIO], [Chen et al., 2023]. AZ505 has been shown to modulate fibrosis and inflammatory signaling in preclinical models by blocking histone and non-histone methylation events. The compound is soluble in DMSO, requires storage at -20°C, and is intended strictly for research purposes. Recent studies highlight AZ505’s value in cancer, fibrosis, and kidney disease models, particularly where SMYD2 is overexpressed or dysregulated.

Biological Rationale

SMYD2 (SET and MYND domain-containing 2) is a protein lysine methyltransferase. It catalyzes methylation of specific lysine residues on histones H2B, H3 (notably H3K4 and H3K36), and H4, as well as non-histone proteins such as p53 and retinoblastoma (Rb) [Chen et al., 2023]. SMYD2-mediated methylation regulates gene transcription, cellular differentiation, and the DNA damage response. Overexpression of SMYD2 has been observed in gastric cancer, esophageal squamous cell carcinoma (ESCC), and models of cisplatin-induced chronic kidney disease (CKD) [Chen et al., 2023]. Dysregulation of histone methylation pathways is increasingly recognized as a hallmark of tumorigenesis and fibrosis [EpigeneticsDomain]. Targeted inhibition of SMYD2 facilitates mechanistic dissection of epigenetic control and provides a route to modulate pathogenic signaling networks.

Mechanism of Action of AZ505, a potent and selective SMYD2 inhibitor

AZ505 is a small molecule inhibitor designed to bind the peptide substrate binding groove of SMYD2. This blocks access of both histone and non-histone substrates, but does not compete with the co-factor S-adenosylmethionine (SAM) [APExBIO]. It is classified as a substrate-competitive inhibitor. Reported inhibition constants are IC₅₀ = 0.12 μM and K_i = 0.3 μM, as determined by in vitro enzymatic assays at physiological pH and ionic strength [APExBIO]. Selectivity data show minimal inhibition of SMYD3, DOT1L, and EZH2 at concentrations up to 83.3 μM, supporting high target specificity [APExBIO], [EpigeneticsDomain]. By preventing lysine methylation, AZ505 modulates gene expression, cell cycle regulation, and signaling pathways associated with inflammation and fibrosis.

Evidence & Benchmarks

• AZ505 reduces SMYD2-mediated methylation of histone H3 at lysine 36 (H3K36) in vitro and in cell-based assays (Chen et al., 2023, DOI).
• In a cisplatin-induced chronic kidney disease mouse model, AZ505 administration led to decreased renal fibrosis, improved renal function, and reduced expression of pro-fibrotic and inflammatory markers (Chen et al., 2023, DOI).
• AZ505 exhibits a high selectivity profile: SMYD3, DOT1L, and EZH2 have IC₅₀ values > 83.3 μM, compared to 0.12 μM for SMYD2 (APExBIO).
• AZ505 significantly inhibits the transition of epithelial cells to mesenchymal phenotype (EMT) and downregulates fibrosis-related proteins in vitro (Chen et al., 2023, DOI).
• AZ505 does not inhibit SMYD2 by competing with SAM, distinguishing it from co-factor-competitive inhibitors (APExBIO).

This article extends the mechanistic detail provided by EpigeneticsDomain by including quantitative benchmarks from recent fibrosis and kidney disease models. For translational guidance, see also Nitrocefin.com, which explores AZ505’s broader impact beyond oncology, while this article emphasizes evidence in renal and fibrotic settings.

Applications, Limits & Misconceptions

AZ505 is primarily utilized in basic and translational research. Key applications include:

• Epigenetic regulation research: Dissecting histone methylation pathways in gene expression and chromatin remodeling [KDM2A.com].
• Cancer biology research: Investigating the role of SMYD2 in oncogenesis, with focus on models of gastric cancer and ESCC [TCS359.com].
• Fibrosis and kidney disease models: Elucidating the contribution of SMYD2-mediated methylation to fibrosis and inflammatory signaling [Chen et al., 2023].

AZ505 should not be used for diagnostic or therapeutic purposes in humans. Its selectivity profile is well-characterized in vitro, but off-target effects in complex biological systems are possible. Effective concentrations and exposure times should be empirically determined for each application.

Common Pitfalls or Misconceptions

• AZ505 is not a pan-methyltransferase inhibitor; it shows minimal inhibitory activity against SMYD3, DOT1L, and EZH2 at standard research concentrations.
• It does not inhibit SMYD2 by SAM co-factor competition; inhibition is substrate-competitive.
• AZ505 is not intended for clinical or diagnostic use; it is for research applications only.
• Compound solubility is optimal in DMSO; aqueous solubility is limited without co-solvents or warming.
• Storage above -20°C or repeated freeze-thaw cycles may compromise compound integrity.

Workflow Integration & Parameters

AZ505 (SKU B1255) is available from APExBIO as a solid or DMSO solution. For optimal solubility, researchers should warm the compound to 37°C and use brief ultrasonic agitation prior to dilution. Working stock solutions are typically prepared at 10–20 mM in DMSO. Recommended storage is at -20°C in airtight, desiccated containers. For in vitro applications, final concentrations range from 0.1–10 μM, depending on cell type and assay. For in vivo studies, dosing regimens should be based on published pharmacokinetics and toxicity data (see Chen et al., 2023).

In cell-based epigenetic assays, AZ505 can improve reproducibility and sensitivity compared to less selective methyltransferase inhibitors [TCS359.com]. This article updates those discussions by including recent evidence from renal fibrosis models and highlighting workflow-specific parameters for reproducible data generation.

Conclusion & Outlook

AZ505 is a validated, potent, and highly selective SMYD2 inhibitor with broad utility in epigenetic regulation and disease modeling. Its substrate-competitive mechanism and high selectivity make it a preferred tool for dissecting SMYD2 function in cancer, fibrosis, and other pathologies with aberrant histone methylation. Ongoing research continues to clarify the full spectrum of biological processes modulated by SMYD2 inhibition. For detailed protocols and ordering, consult the AZ505 product page at APExBIO.
For further reading on translational and advanced applications, see SM-406.com, which emphasizes novel disease models and extends the practical framework provided here.